Lunai Bioworks (LNAI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jul, 2026Opening remarks and agenda
CEO welcomed shareholders and confirmed quorum was present to proceed with the meeting.
Purpose of the meeting was outlined, with two proposals set for shareholder vote.
Shareholder proposals
Proposal 1: Approve an amendment to the certificate of incorporation to allow a reverse stock split at a ratio between 1:3 and 1:30, with the exact ratio to be determined by the board.
Proposal 2: Approve adjournment of the meeting if necessary to solicit additional proxies for Proposal 1.
Board recommended shareholders vote in favor of both proposals.
Overview of voting outcomes
Polls were opened and closed for voting on both proposals during the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lunai Bioworks
- Net loss narrowed to $1.55M on lower expenses and a $12M gain from subsidiary bankruptcy.LNAI
Q3 202615 May 2026 - Special meeting to vote on reverse split and merger-related actions after Neurobridge acquisition.LNAIProxy filing1 May 2026
- Virtual Special Meeting postponed to May 8, 2026, to vote on a reverse stock split and adjournment.LNAIProxy filing29 Apr 2026
- Shareholders will vote on a reverse stock split aimed at preserving Nasdaq listing and liquidity.LNAIProxy filing15 Apr 2026
- Shareholders will vote on a reverse stock split aimed at preserving Nasdaq listing and liquidity.LNAIProxy filing13 Apr 2026
- Shareholders to vote on a reverse stock split aimed at preserving Nasdaq listing and liquidity.LNAIProxy filing2 Apr 2026
- Patented AI platform delivers de-risked CNS and oncology assets, driving pharma partnerships.LNAIInvestor presentation17 Feb 2026
- Returned to profitability with $1.0M net income, but faces funding and delisting risks.LNAIQ2 202617 Feb 2026
- Shelf registration enables up to $200M in offerings to fund biotech and AI-driven cancer initiatives.LNAIRegistration Filing16 Dec 2025